These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 10631623)

  • 1. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
    Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
    J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
    Liston HL; DeVane CL; Boulton DW; Risch SC; Markowitz JS; Goldman J
    J Clin Psychopharmacol; 2002 Apr; 22(2):169-73. PubMed ID: 11910262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
    Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
    J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
    DeVane CL; Donovan JL; Liston HL; Markowitz JS; Cheng KT; Risch SC; Willard L
    J Clin Psychopharmacol; 2004 Feb; 24(1):4-10. PubMed ID: 14709940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High venlafaxine serum levels after prior fluoxetine medication.
    Gerbaulet M; Engel A; Hiemke C; Dahmen N
    J Clin Psychopharmacol; 2012 Apr; 32(2):295-7. PubMed ID: 22388163
    [No Abstract]   [Full Text] [Related]  

  • 11. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
    Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
    J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
    Binkhorst L; Bannink M; de Bruijn P; Ruit J; Droogendijk H; van Alphen RJ; den Boer TD; Lam MH; Jager A; van Gelder T; Mathijssen RH
    Clin Pharmacokinet; 2016 Feb; 55(2):249-55. PubMed ID: 26446141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 inhibition in patients treated with sertraline.
    Sproule BA; Otton SV; Cheung SW; Zhong XH; Romach MK; Sellers EM
    J Clin Psychopharmacol; 1997 Apr; 17(2):102-6. PubMed ID: 10950472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.
    Wilner KD; Demattos SB; Anziano RJ; Apseloff G; Gerber N
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):43S-47S. PubMed ID: 10771453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
    Luong TT; Powers CN; Reinhardt BJ; Weina PJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
    Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
    Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.